NLRP3 and myocardial ischemia: Our findings elucidated that tilianin disrupted the NLRP3-NEK7 interaction, proposing a supplemental mechanism by which tilianin treatment could mitigate NLRP3 inflammasome activation and alleviate myocardial ischemia/reperfusion injury (Figure 7).